UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 427

Sortiert nach

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

The Lancet infectious diseases, 2014-07, Vol.14 (7), p.572-580

2014

Volltextzugriff (PDF)

Clinical Management of Ebola Virus Disease in the United States and Europe

The New England journal of medicine, 2016-02, Vol.374 (7), p.636-646

2016

Volltextzugriff (PDF)

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

The New England journal of medicine, 2014-07, Vol.371 (3), p.234-247

2014

Volltextzugriff (PDF)

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

The New England journal of medicine, 2006-01, Vol.354 (3), p.251-260

2006

Volltextzugriff (PDF)

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

The Lancet infectious diseases, 2014-07, Vol.14 (7), p.581-589

2014

Volltextzugriff (PDF)

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues

AIDS (London), 2015-09, Vol.29 (14), p.1811-1820

2015

Volltextzugriff (PDF)

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

PloS one, 2019-01, Vol.14 (1), p.e0209911-e0209911

2019

Volltextzugriff (PDF)

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

Antiviral therapy, 2013-01, Vol.18 (7), p.905-913

2013

Volltextzugriff (PDF)

Persistence and infectivity of Zika virus in semen after returning from endemic areas: Report of 5 cases

Journal of clinical virology, 2017-11, Vol.96, p.110-115

2017

Volltextzugriff (PDF)

A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy

The Journal of infectious diseases, 2008-07, Vol.198 (2), p.234-240

2008

Volltextzugriff (PDF)

Which trial do we need? Management of elderly, fragile, fully vaccinated patients hospitalized for SARS-CoV-2 infection

Clinical microbiology and infection, 2023-04, Vol.29 (4), p.419-421

2023

Volltextzugriff (PDF)

Three Years of the Coronavirus Disease 2019 Pandemic in a European Region: A Population-Based Longitudinal Assessment in Madrid Between 2020 and 2022

Open forum infectious diseases, 2024-01, Vol.11 (1), p.ofad635-ofad635

2024

Volltextzugriff (PDF)

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)

Journal of acquired immune deficiency syndromes (1999), 2005-11, Vol.40 (3), p.280

2005

Volltextzugriff (PDF)

Probable sexual transmission of Zika virus from a vasectomised man

The Lancet infectious diseases, 2016-10, Vol.16 (10), p.1107-1107

2016

Volltextzugriff (PDF)

Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality

Clinical infectious diseases, 2023-03, Vol.76 (6), p.1136-1141

2023

Volltextzugriff (PDF)

Monocyte Activation and Ageing Biomarkers in the Development of Cardiovascular Ischaemic Events or Diabetes in People with HIV

Microorganisms (Basel), 2023-07, Vol.11 (7), p.1818

2023

Volltextzugriff (PDF)

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

The Lancet infectious diseases, 2012-02, Vol.12 (2), p.111-118

2012

Volltextzugriff (PDF)

Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study

Journal of acquired immune deficiency syndromes (1999), 2014-01, Vol.65 (1), p.82

2014

Volltextzugriff (PDF)

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

Journal of acquired immune deficiency syndromes (1999), 2016-04, Vol.71 (5), p.530

2016

Volltextzugriff (PDF)

The Current Mismatch Between COVID-19 Clinical Trial Design and the Evolving Profile of Hospitalized Patients: A Retrospective Cohort Analysis

Clinical infectious diseases, 2024-04, Vol.78 (4), p.918-921

2024

Volltextzugriff (PDF)

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Journal of acquired immune deficiency syndromes (1999), 2020-03, Vol.83 (3), p.310

2020

Volltextzugriff (PDF)

Transient elastography to rule out esophageal varices and portal hypertensive gastropathy in HIV-infected individuals with liver cirrhosis

AIDS (London), 2012-09, Vol.26 (14), p.1807-1812

2012

Volltextzugriff (PDF)

1 – 25 von 427

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(401)
Mit Volltextzugriff
(371)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

Clinical Management of Ebola Virus Disease in the United States and Europe

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

Persistence and infectivity of Zika virus in semen after returning from endemic areas: Report of 5 cases

A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy

Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain

Which trial do we need? Management of elderly, fragile, fully vaccinated patients hospitalized for SARS-CoV-2 infection

Three Years of the Coronavirus Disease 2019 Pandemic in a European Region: A Population-Based Longitudinal Assessment in Madrid Between 2020 and 2022

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)

Probable sexual transmission of Zika virus from a vasectomised man

Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality

Monocyte Activation and Ageing Biomarkers in the Development of Cardiovascular Ischaemic Events or Diabetes in People with HIV

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

The Current Mismatch Between COVID-19 Clinical Trial Design and the Evolving Profile of Hospitalized Patients: A Retrospective Cohort Analysis

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Transient elastography to rule out esophageal varices and portal hypertensive gastropathy in HIV-infected individuals with liver cirrhosis

Suchergebnisse filtern